<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01952574</url>
  </required_header>
  <id_info>
    <org_study_id>20120178</org_study_id>
    <secondary_id>2012-005331-90</secondary_id>
    <nct_id>NCT01952574</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the effect of erenumab compared to placebo on the change from baseline in&#xD;
      monthly migraine days in participants with episodic migraine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is composed of an initial screening phase (up to 3 weeks), a 4-week baseline phase,&#xD;
      a 12-week double-blind treatment phase (DBTP), an open-label treatment phase (OLTP) for up to&#xD;
      256 weeks, and an 8-week safety follow-up (12 weeks after the last dose of investigational&#xD;
      product [IP]).&#xD;
&#xD;
      In the DBTP participants were to be randomized in a 3:2:2:2 ratio to placebo, erenumab 7 mg,&#xD;
      erenumab 21 mg, or erenumab 70 mg.&#xD;
&#xD;
      During the open-label treatment phase, participants were to receive erenumab 70 mg QM from&#xD;
      week 12 to week 264. After implementation of Protocol Amendment 3 (07 April 2016),&#xD;
      participants remaining in the OLTP increased their dose to erenumab 140 mg QM up to week 264.&#xD;
      The safety follow-up increased from an 8-week safety follow-up to a 12-week safety follow-up&#xD;
      (16 weeks after the last dose of investigational product).&#xD;
&#xD;
      During the OLTP participants enrolled at sites in the United States could enroll in an&#xD;
      optional clinical home use (CHU) substudy, per a country-specific protocol amendment dated 20&#xD;
      June 2016. Participants in the CHU substudy were to be randomized 1:1 into 1 of 2 treatment&#xD;
      groups: erenumab 140 mg using a prefilled syringe or erenumab 140 mg using an&#xD;
      autoinjector/pen. Day 1 of the CHU substudy corresponded with any OLTP study visit up through&#xD;
      Week 256, as long as the participant had received at least 2 doses of erenumab 140 mg. During&#xD;
      the CHU substudy, participants initially self-administered IP under site supervision on&#xD;
      substudy day 1, and then self-administered IP at home on substudy days 29 and 57.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 6, 2013</start_date>
  <completion_date type="Actual">November 12, 2019</completion_date>
  <primary_completion_date type="Actual">September 25, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In the DBTP participants were randomized to one of four arms. In the optional CHU substudy participants were randomized into one of two treatment groups.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Monthly Migraine Days at Week 12</measure>
    <time_frame>4-week baseline phase and the last 4 weeks of the 12-week double-blind treatment phase</time_frame>
    <description>A migraine day was any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura. The change from baseline in monthly migraine days was calculated as the number of migraine days during the last 4 weeks of the 12-week double-blind treatment phase - the number of migraine days during the 4-week baseline phase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CHU Substudy: Number of Participants Who Self-administered a Full Dose, Partial Dose, or No Dose of Erenumab</measure>
    <time_frame>CHU substudy day 29 (week 4) and day 57 (week 8)</time_frame>
    <description>To assess participants ability to administer a full dose of erenumab in home-use at day 29 (week 4) and day 57 (week 8), site staff called participants and asked whether the participant administered a full, partial, or no dose of erenumab. A full dose means that the entire volume of both prefilled syringes or autoinjector/pens were injected. Discontinued prior to dosing day indicates participants who had discontinued the investigational product and did not attempt to self-administer on day 29 or 57.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least a 50% Reduction From Baseline in Monthly Migraine Days at Week 12</measure>
    <time_frame>4-week baseline phase and the last 4 weeks of the 12-week double-blind treatment phase</time_frame>
    <description>A migraine day was any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined either as a migraine without aura or a migraine with aura. Monthly migraine days were calculated as the number of migraine days in the 4-week baseline phase and during the last 4 weeks of double-blind treatment. At least a 50% reduction from baseline in monthly migraine days was determined if the change in monthly migraine days from the 4-week baseline phase to the last 4 weeks of the 12-week double-blind treatment phase * 100 / baseline monthly migraine days was less than or equal to -50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Monthly Migraine Attacks at Week 12</measure>
    <time_frame>4-week baseline phase and the last 4 weeks of the 12-week double-blind treatment phase</time_frame>
    <description>A migraine attack is an episode of any qualified migraine headache or migraine specific medication intakes for aura only. A migraine attack that was interrupted by sleep or that temporarily remits and then recurs within 48 hours or an attack treated successfully with medication but that relapses within 48 hours was considered to be one attack.&#xD;
The change from baseline in monthly migraine attacks was calculated as the number of migraine attacks during the last 4 weeks of the 12-week double-blind treatment phase - the number of migraine attacks during the 4-week baseline phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events in the Double-blind Treatment Phase</measure>
    <time_frame>From first dose of study drug in the double-blind treatment phase until the first dose of study drug in the open-label treatment phase (12 weeks) or up to 12 weeks after last dose for participants who did not enter the open-label treatment phase.</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical trial subject, including worsening of a pre-existing medical condition and laboratory value changes that require treatment or adjustment in current therapy.&#xD;
AEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03:&#xD;
Mild; asymptomatic or mild symptoms&#xD;
Moderate; minimal, local or noninvasive intervention indicated; limiting daily activities&#xD;
Severe or medically significant but not immediately life-threatening; hospitalization indicated; disabling; limiting self-care&#xD;
Life-threatening consequences; urgent intervention indicated&#xD;
Death related to AE&#xD;
A serious adverse event is an AE that meets at least 1 of the following criteria:&#xD;
fatal&#xD;
life threatening&#xD;
requires in-patient hospitalization or prolongation of existing hospitalization&#xD;
results in persistent or significant disability/incapacity&#xD;
congenital anomaly/birth defect&#xD;
other medically important serious event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events in the Open-label Treatment Phase</measure>
    <time_frame>From first dose in the open-label treatment phase up to 12 weeks (participants receiving 70 mg only) or 16 weeks (participants with dose increased to 140 mg) after the last dose; a maximum of 268 weeks.</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical trial subject, including worsening of a pre-existing medical condition and laboratory value changes that require treatment or adjustment in current therapy.&#xD;
AEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03:&#xD;
Mild; asymptomatic or mild symptoms&#xD;
Moderate; minimal, local or noninvasive intervention indicated; limiting daily activities&#xD;
Severe or medically significant but not immediately life-threatening; hospitalization indicated; disabling; limiting self-care&#xD;
Life-threatening consequences; urgent intervention indicated&#xD;
Death related to AE&#xD;
A serious adverse event is an AE that meets at least 1 of the following criteria:&#xD;
fatal&#xD;
life threatening&#xD;
requires in-patient hospitalization or prolongation of existing hospitalization&#xD;
results in persistent or significant disability/incapacity&#xD;
congenital anomaly/birth defect&#xD;
other medically important serious event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CHU Substudy: Number of Participants With Treatment-emergent Adverse Events During the CHU Substudy</measure>
    <time_frame>From first dose in the CHU substudy to end of substudy (up to 12 weeks)</time_frame>
    <description>AEs were graded using the CTCAE version 4.03:&#xD;
Mild; asymptomatic or mild symptoms&#xD;
Moderate; minimal, local or noninvasive intervention indicated; limiting daily activities&#xD;
Severe or medically significant but not immediately life-threatening; hospitalization indicated; disabling; limiting self-care&#xD;
Life-threatening consequences; urgent intervention indicated&#xD;
Death related to AE&#xD;
A serious adverse event is an AE that meets at least 1 of the following criteria:&#xD;
fatal&#xD;
life threatening&#xD;
requires in-patient hospitalization or prolongation of existing hospitalization&#xD;
results in persistent or significant disability/incapacity&#xD;
congenital anomaly/birth defect&#xD;
other medically important serious event An adverse device effect is any AE related to the use of a medical device, including AEs resulting from insufficient or inadequate instructions for use, any malfunction of the device, or use error or from intentional misuse of the device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Anti-erenumab Antibodies During the Double-blind Treatment Phase</measure>
    <time_frame>12 weeks</time_frame>
    <description>Two validated assays were used to detect the presence of anti-erenumab antibodies. First, an electrochemiluminescent bridging immunoassay was used to detect binding antibodies (screening assay) and confirm antibodies (confirmatory assay) capable of binding erenumab. Second, a cell-based bioassay was used to test positive binding antibody samples for neutralizing activity against erenumab.&#xD;
Participants who developed anti-erenumab antibodies are participants who were negative or had no result at baseline but positive at any time postbaseline during the DBTP.&#xD;
If a sample was positive for binding antibodies and demonstrated neutralizing activity at the same time point, the participant was defined as positive for neutralizing antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Anti-erenumab Antibodies During the Open-label Treatment Phase</measure>
    <time_frame>From week 12 up to 12 weeks (participants receiving 70 mg only) or 16 weeks (participants with dose increased to 140 mg) after the last dose; maximum 268 weeks.</time_frame>
    <description>Two validated assays were used to detect the presence of anti-erenumab antibodies. First, an electrochemiluminescent bridging immunoassay was used to detect binding antibodies (screening assay) and confirm antibodies (confirmatory assay) capable of binding erenumab. Second, a cell-based bioassay was used to test positive binding antibody samples for neutralizing activity against erenumab.&#xD;
Participants who developed anti-erenumab antibodies are participants who were negative prior to the first OLTP dose but positive at any time during the OLTP, or participants with no data prior to first dose in OLTP with any post-baseline positive results.&#xD;
If a sample was positive for binding antibodies and demonstrated neutralizing activity at the same time point, the participant was defined as positive for neutralizing antibodies.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">483</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.&#xD;
In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erenumab 7 mg QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received erenumab 7 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.&#xD;
In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erenumab 21 mg QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received erenumab 21 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.&#xD;
In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erenumab 70 mg QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.&#xD;
In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHU Substudy: Erenumab 140 mg PFS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the open-label treatment phase in the United States randomized to self-administer 140 mg erenumab via two 70 mg injections using a prefilled syringe (PFS) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHU Substudy: Erenumab 140 mg AI/Pen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the open-label treatment phase in the United States randomized to self-administer 140 mg erenumab via two 70 mg injections using an autoinjector/pen (AI)/pen) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erenumab</intervention_name>
    <description>Administered by study site staff once a month (QM) as a subcutaneous injection</description>
    <arm_group_label>Erenumab 21 mg QM</arm_group_label>
    <arm_group_label>Erenumab 7 mg QM</arm_group_label>
    <arm_group_label>Erenumab 70 mg QM</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>AMG 334</other_name>
    <other_name>Aimovig™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered by study site staff once a month (QM) as a subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erenumab PFS</intervention_name>
    <description>Erenumab supplied in a single-use prefilled syringe for self-administration in the CHU substudy</description>
    <arm_group_label>CHU Substudy: Erenumab 140 mg PFS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erenumab AI/Pen</intervention_name>
    <description>Erenumab supplied in a single-use autoinjector/pen for self-administration in the CHU substudy</description>
    <arm_group_label>CHU Substudy: Erenumab 140 mg AI/Pen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of migraine for more than12 months prior to screening&#xD;
&#xD;
          -  Migraine frequency: ≥ 4 and ≤ 14 migraine days per month in each of the 3 months prior&#xD;
             to screening and during baseline phase&#xD;
&#xD;
          -  Headache frequency: &lt; 15 headache days per month (with &gt; 50% of the headache days&#xD;
             being migraine days) in each of the 3 months prior to screening and during baseline&#xD;
             phase&#xD;
&#xD;
          -  Demonstrated at least 80% compliance with the eDiary during baseline phase&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Older than 50 years of age at migraine onset&#xD;
&#xD;
          -  History of cluster headache or basilar or hemiplegic migraine headache&#xD;
&#xD;
          -  Unable to differentiate migraine from other headaches&#xD;
&#xD;
          -  No therapeutic response with &gt; 2 of the following eight medication categories for&#xD;
             prophylactic treatment of migraine after an adequate therapeutic trial. Medication&#xD;
             categories are:&#xD;
&#xD;
               -  Category 1: Divalproex sodium, sodium valproate&#xD;
&#xD;
               -  Category 2: Topiramate&#xD;
&#xD;
               -  Category 3: Beta blockers (for example: atenolol, bisoprolol, metoprolol,&#xD;
                  nadolol, nebivolol, pindolol, propranolol, timolol)&#xD;
&#xD;
               -  Category 4: Tricyclic antidepressants (for example: amitriptyline, nortriptyline,&#xD;
                  protriptyline)&#xD;
&#xD;
               -  Category 5: Venlafaxine, desvenlafaxine, duloxetine, milnacipran&#xD;
&#xD;
               -  Category 6: Flunarizine, verapamil&#xD;
&#xD;
               -  Category 7: Lisinopril, candesartan&#xD;
&#xD;
               -  Category 8: Butterbur, feverfew, magnesium (≥ 600 mg/day), riboflavin (≥ 100&#xD;
                  mg/day)&#xD;
&#xD;
          -  Overuse of acute migraine medications in any month during the 3 months prior to&#xD;
             screening or during screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4S 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mikkeli</city>
        <zip>50100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10409</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bochum</city>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <zip>45133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamar</city>
        <zip>2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sandvika</city>
        <zip>1337</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stavanger</city>
        <zip>4005</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ålesund</city>
        <zip>6003</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Falköping</city>
        <zip>521 37</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <zip>222 22</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <zip>112 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <zip>114 33</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vällingby</city>
        <zip>162 68</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Apr;15(4):382-90. doi: 10.1016/S1474-4422(16)00019-3. Epub 2016 Feb 12.</citation>
    <PMID>26879279</PMID>
  </reference>
  <reference>
    <citation>Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. Neurology. 2017 Sep 19;89(12):1237-1243. doi: 10.1212/WNL.0000000000004391. Epub 2017 Aug 23.</citation>
    <PMID>28835404</PMID>
  </reference>
  <reference>
    <citation>Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, Rippon GA, Klatt J, Xue F, Chia V, Zhang F, Cheng S, Mikol DD. Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia. 2019 Oct;39(11):1455-1464. doi: 10.1177/0333102419854082. Epub 2019 May 30.</citation>
    <PMID>31146544</PMID>
  </reference>
  <reference>
    <citation>Cheng S, Picard H, Zhang F, Eisele O, Mikol DD. Efficacy and safety of erenumab for migraine prevention: an overview. Japanese Journal of Headache. 2019; 45 : 493-505.</citation>
  </reference>
  <reference>
    <citation>[ Aug 19, 2021, 1:12 PM PDT - Gonzalez, Alexandria ] enhanced content not added to quosa Ashina M, Goadsby PJ, Reuter U, et al. Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial [published online ahead of print, 2021 Jan 5]. Eur J Neurol. 2021;10.1111/ene.14715. doi:10.1111/ene.14715</citation>
  </reference>
  <reference>
    <citation>[ Aug 19, 2021, 1:13 PM PDT - Gonzalez, Alexandria ] enhanced content not added to quosa Ashina M, Goadsby PJ, Reuter U, et al. Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial [published online ahead of print, 2021 Jan 5]. Eur J Neurol. 2021;10.1111/ene.14715. doi:10.1111/ene.14715</citation>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 30, 2013</study_first_submitted>
  <study_first_submitted_qc>September 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2013</study_first_posted>
  <results_first_submitted>June 11, 2018</results_first_submitted>
  <results_first_submitted_qc>June 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 10, 2018</results_first_posted>
  <disposition_first_submitted>April 30, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 30, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 19, 2015</disposition_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>migraine, headache, prevention, prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erenumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 59 centers in North America (Canada, USA) and Europe (Denmark, Finland, Germany, Norway, Sweden, and Portugal).&#xD;
The study consisted of a 12-week double-blind treatment phase (DBTP) and a 256-week open-label treatment phase (OLTP) followed by a safety follow-up of 8 to 12 weeks (12 -16 weeks after last dose). The OLTP portion of the study was not conducted in Norway.</recruitment_details>
      <pre_assignment_details>Participants were randomized 3:2:2:2 to receive placebo, erenumab 7 mg, erenumab 21 mg, or erenumab 70 mg once a month (QM) in the double-blind phase. Randomization was stratified by region (North America vs. Europe).&#xD;
During the open-label treatment phase, participants in the United States (US) could participate in an optional Clinical Home Use (CHU) substudy.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DBTP: Placebo QM</title>
          <description>Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
        </group>
        <group group_id="P2">
          <title>DBTP: Erenumab 7 mg QM</title>
          <description>Participants received erenumab 7 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
        </group>
        <group group_id="P3">
          <title>DBTP: Erenumab 21 mg QM</title>
          <description>Participants received erenumab 21 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
        </group>
        <group group_id="P4">
          <title>DBTP: Erenumab 70 mg QM</title>
          <description>Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
        </group>
        <group group_id="P5">
          <title>OLTP: Erenumab 70/140 mg QM</title>
          <description>Participants received 70 mg erenumab QM from the beginning of the OLTP (week 12). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM.</description>
        </group>
        <group group_id="P6">
          <title>CHU Substudy: Erenumab 140 mg by Prefilled Syringe</title>
          <description>Participants in the open-label treatment phase in the United States randomized to self-administer 140 mg erenumab via two 70 mg injections using a prefilled syringe (PFS) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).</description>
        </group>
        <group group_id="P7">
          <title>CHU Substudy: Erenumab 140 mg Autoinjector/Pen</title>
          <description>Participants in the open-label treatment phase in the United States randomized to self-administer 140 mg erenumab via two 70 mg injections using an autoinjector (AI)/pen on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="108"/>
                <participants group_id="P4" count="107"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="105"/>
                <participants group_id="P4" count="106"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="105"/>
                <participants group_id="P3" count="99"/>
                <participants group_id="P4" count="101"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-label Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="383"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received 70 mg Erenumab</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="383"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received 140 mg Erenumab</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="250"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="221"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="162"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="121"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Decision by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Clinical Home Use Substudy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="42"/>
                <participants group_id="P7" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="39"/>
                <participants group_id="P7" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Decision by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
        </group>
        <group group_id="B2">
          <title>Erenumab 7 mg QM</title>
          <description>Participants received erenumab 7 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
        </group>
        <group group_id="B3">
          <title>Erenumab 21 mg QM</title>
          <description>Participants received erenumab 21 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
        </group>
        <group group_id="B4">
          <title>Erenumab 70 mg QM</title>
          <description>Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="160"/>
            <count group_id="B2" value="108"/>
            <count group_id="B3" value="108"/>
            <count group_id="B4" value="107"/>
            <count group_id="B5" value="483"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="160"/>
                    <count group_id="B2" value="108"/>
                    <count group_id="B3" value="108"/>
                    <count group_id="B4" value="107"/>
                    <count group_id="B5" value="483"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.4" spread="10.0"/>
                    <measurement group_id="B2" value="40.3" spread="10.9"/>
                    <measurement group_id="B3" value="39.9" spread="12.3"/>
                    <measurement group_id="B4" value="42.6" spread="9.9"/>
                    <measurement group_id="B5" value="41.1" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="160"/>
                    <count group_id="B2" value="108"/>
                    <count group_id="B3" value="108"/>
                    <count group_id="B4" value="107"/>
                    <count group_id="B5" value="483"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="389"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="160"/>
                    <count group_id="B2" value="108"/>
                    <count group_id="B3" value="108"/>
                    <count group_id="B4" value="107"/>
                    <count group_id="B5" value="483"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="106"/>
                    <measurement group_id="B5" value="453"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="160"/>
                    <count group_id="B2" value="108"/>
                    <count group_id="B3" value="108"/>
                    <count group_id="B4" value="107"/>
                    <count group_id="B5" value="483"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="103"/>
                    <measurement group_id="B5" value="442"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region</title>
          <description>Region is based on actual data collected at study baseline instead of randomization stratification.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="160"/>
                    <count group_id="B2" value="108"/>
                    <count group_id="B3" value="108"/>
                    <count group_id="B4" value="107"/>
                    <count group_id="B5" value="483"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>North America</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="259"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Europe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Monthly Migraine Days</title>
          <description>A migraine day was any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine without aura or a migraine with aura. Monthly migraine days were calculated as the number of migraine days in the 4-week baseline phase.</description>
          <population>Participants with available baseline data</population>
          <units>migraine days/month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="160"/>
                    <count group_id="B2" value="108"/>
                    <count group_id="B3" value="108"/>
                    <count group_id="B4" value="106"/>
                    <count group_id="B5" value="482"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.77" spread="2.72"/>
                    <measurement group_id="B2" value="8.62" spread="2.79"/>
                    <measurement group_id="B3" value="8.93" spread="2.88"/>
                    <measurement group_id="B4" value="8.58" spread="2.49"/>
                    <measurement group_id="B5" value="8.73" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Monthly Migraine Days at Week 12</title>
        <description>A migraine day was any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura. The change from baseline in monthly migraine days was calculated as the number of migraine days during the last 4 weeks of the 12-week double-blind treatment phase - the number of migraine days during the 4-week baseline phase.</description>
        <time_frame>4-week baseline phase and the last 4 weeks of the 12-week double-blind treatment phase</time_frame>
        <population>Participants who received at least 1 dose of investigational product (IP) and had ≥ 4 migraine days during the 4-week baseline phase (efficacy analysis set), and with at least one change from baseline value in monthly migraine days.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Erenumab 7 mg QM</title>
            <description>Participants received erenumab 7 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Erenumab 21 mg QM</title>
            <description>Participants received erenumab 21 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
          <group group_id="O4">
            <title>Erenumab 70 mg QM</title>
            <description>Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Monthly Migraine Days at Week 12</title>
          <description>A migraine day was any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined as a migraine with or without aura. The change from baseline in monthly migraine days was calculated as the number of migraine days during the last 4 weeks of the 12-week double-blind treatment phase - the number of migraine days during the 4-week baseline phase.</description>
          <population>Participants who received at least 1 dose of investigational product (IP) and had ≥ 4 migraine days during the 4-week baseline phase (efficacy analysis set), and with at least one change from baseline value in monthly migraine days.</population>
          <units>migraine days / month</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="0.31"/>
                    <measurement group_id="O2" value="-2.18" spread="0.36"/>
                    <measurement group_id="O3" value="-2.39" spread="0.38"/>
                    <measurement group_id="O4" value="-3.40" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The primary analysis utilized a generalized linear mixed model which included treatment, visit, treatment by visit, the stratification factor region, and baseline value as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>To maintain the type I error at ≤ 0.05, the pairwise comparison was tested in a sequential testing procedure in the order of erenumab 70 mg vs placebo, 21 mg vs placebo, and 7 mg vs placebo. The lower dose group was only to be tested when the higher dose group was tested as significant.</non_inferiority_desc>
            <p_value>0.021</p_value>
            <method>Generalized Linear Mixed Model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.06</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary analysis utilized a generalized linear mixed model which included treatment, visit, treatment by visit, the stratification factor region, and baseline value as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>To maintain the type I error at ≤ 0.05, the pairwise comparison was tested in a sequential testing procedure in the order of erenumab 70 mg vs placebo, 21 mg vs placebo, and 7 mg vs placebo. The lower dose group was only to be tested when the higher dose group was tested as significant.</non_inferiority_desc>
            <p_value>0.83</p_value>
            <method>Generalized Linear Mixed Model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis utilized a generalized linear mixed model which included treatment, visit, treatment by visit, the stratification factor region, and baseline value as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>To maintain the type I error at ≤ 0.05, the pairwise comparison was tested in a sequential testing procedure in the order of erenumab 70 mg vs placebo, 21 mg vs placebo, and 7 mg vs placebo. The lower dose group was only to be tested when the higher dose group was tested as significant.</non_inferiority_desc>
            <p_value>0.82</p_value>
            <method>Generalized Linear Mixed Model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.11</param_value>
            <ci_percent>92</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least a 50% Reduction From Baseline in Monthly Migraine Days at Week 12</title>
        <description>A migraine day was any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined either as a migraine without aura or a migraine with aura. Monthly migraine days were calculated as the number of migraine days in the 4-week baseline phase and during the last 4 weeks of double-blind treatment. At least a 50% reduction from baseline in monthly migraine days was determined if the change in monthly migraine days from the 4-week baseline phase to the last 4 weeks of the 12-week double-blind treatment phase * 100 / baseline monthly migraine days was less than or equal to -50%.</description>
        <time_frame>4-week baseline phase and the last 4 weeks of the 12-week double-blind treatment phase</time_frame>
        <population>Participants who received at least 1 dose of investigational product and had ≥ 4 migraine days during the 4-week baseline phase (efficacy analysis set) with available data at week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Erenumab 7 mg QM</title>
            <description>Participants received erenumab 7 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Erenumab 21 mg QM</title>
            <description>Participants received erenumab 21 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
          <group group_id="O4">
            <title>Erenumab 70 mg QM</title>
            <description>Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least a 50% Reduction From Baseline in Monthly Migraine Days at Week 12</title>
          <description>A migraine day was any calendar day in which the participant experienced a qualified migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified migraine headache was defined either as a migraine without aura or a migraine with aura. Monthly migraine days were calculated as the number of migraine days in the 4-week baseline phase and during the last 4 weeks of double-blind treatment. At least a 50% reduction from baseline in monthly migraine days was determined if the change in monthly migraine days from the 4-week baseline phase to the last 4 weeks of the 12-week double-blind treatment phase * 100 / baseline monthly migraine days was less than or equal to -50%.</description>
          <population>Participants who received at least 1 dose of investigational product and had ≥ 4 migraine days during the 4-week baseline phase (efficacy analysis set) with available data at week 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9"/>
                    <measurement group_id="O2" value="28.8"/>
                    <measurement group_id="O3" value="34.4"/>
                    <measurement group_id="O4" value="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The generalized linear mixed model includes data for all participants in the efficacy analysis set with at least one percent change from baseline value in monthly migraine days (152 participants in the placebo group and 104 in the erenumab 70 mg group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Generalised Linear Mixed Model</method>
            <method_desc>Generalized linear mixed model including treatment, visit, treatment by visit, stratification factor region, and baseline value as covariates.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>3.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The generalized linear mixed model includes data for all participants in the efficacy analysis set with at least one change from baseline value in monthly migraine days (152 participants in the placebo group and 99 in the erenumab 21 mg group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>Generalized Linear Mixed Model</method>
            <method_desc>Generalized linear mixed model including treatment, visit, treatment by visit, stratification factor region, and baseline value as covariates.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>2.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The generalized linear mixed model includes data for all participants in the efficacy analysis set with at least one change from baseline value in monthly migraine days (152 participants in the placebo group and 107 in the erenumab 7 mg group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.80</p_value>
            <method>Generalized Linear Mixed Model</method>
            <method_desc>Generalized linear mixed model including treatment, visit, treatment by visit, stratification factor region, and baseline value as covariates.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Monthly Migraine Attacks at Week 12</title>
        <description>A migraine attack is an episode of any qualified migraine headache or migraine specific medication intakes for aura only. A migraine attack that was interrupted by sleep or that temporarily remits and then recurs within 48 hours or an attack treated successfully with medication but that relapses within 48 hours was considered to be one attack.&#xD;
The change from baseline in monthly migraine attacks was calculated as the number of migraine attacks during the last 4 weeks of the 12-week double-blind treatment phase - the number of migraine attacks during the 4-week baseline phase.</description>
        <time_frame>4-week baseline phase and the last 4 weeks of the 12-week double-blind treatment phase</time_frame>
        <population>Participants who received at least 1 dose of investigational product and had ≥ 4 migraine days during the 4-week baseline phase (efficacy analysis set), and with at least one change from baseline value in monthly migraine attacks.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Erenumab 7 mg QM</title>
            <description>Participants received erenumab 7 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Erenumab 21 mg QM</title>
            <description>Participants received erenumab 21 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
          <group group_id="O4">
            <title>Erenumab 70 mg QM</title>
            <description>Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Monthly Migraine Attacks at Week 12</title>
          <description>A migraine attack is an episode of any qualified migraine headache or migraine specific medication intakes for aura only. A migraine attack that was interrupted by sleep or that temporarily remits and then recurs within 48 hours or an attack treated successfully with medication but that relapses within 48 hours was considered to be one attack.&#xD;
The change from baseline in monthly migraine attacks was calculated as the number of migraine attacks during the last 4 weeks of the 12-week double-blind treatment phase - the number of migraine attacks during the 4-week baseline phase.</description>
          <population>Participants who received at least 1 dose of investigational product and had ≥ 4 migraine days during the 4-week baseline phase (efficacy analysis set), and with at least one change from baseline value in monthly migraine attacks.</population>
          <units>migraine attacks/month</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="0.17"/>
                    <measurement group_id="O2" value="-1.07" spread="0.20"/>
                    <measurement group_id="O3" value="-1.42" spread="0.21"/>
                    <measurement group_id="O4" value="-1.84" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Generalized Linear Mixed Model</method>
            <method_desc>Generalized linear mixed model including treatment, visit, treatment by visit, the stratification factor region, and baseline value as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.92</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>Generalized Linear Mixed Model</method>
            <method_desc>Generalized linear mixed model including treatment, visit, treatment by visit, the stratification factor region, and baseline value as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Generalized Linear Mixed Model</method>
            <method_desc>Generalized linear mixed model including treatment, visit, treatment by visit, the stratification factor region, and baseline value as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CHU Substudy: Number of Participants Who Self-administered a Full Dose, Partial Dose, or No Dose of Erenumab</title>
        <description>To assess participants ability to administer a full dose of erenumab in home-use at day 29 (week 4) and day 57 (week 8), site staff called participants and asked whether the participant administered a full, partial, or no dose of erenumab. A full dose means that the entire volume of both prefilled syringes or autoinjector/pens were injected. Discontinued prior to dosing day indicates participants who had discontinued the investigational product and did not attempt to self-administer on day 29 or 57.</description>
        <time_frame>CHU substudy day 29 (week 4) and day 57 (week 8)</time_frame>
        <population>Participants enrolled in the CHU substudy who received at least 1 dose of investigational product in the substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>CHU Substudy: Erenumab 140 mg Prefilled Syringe</title>
            <description>Participants in the open-label treatment phase in the United States self-administered 140 mg erenumab via two 70 mg injections using a prefilled syringe (PFS) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).</description>
          </group>
          <group group_id="O2">
            <title>CHY SubStudy: Erenumab 140 mg Autoinjector/Pen</title>
            <description>Participants in the open-label treatment phase in the United States self-administered 140 mg erenumab via two 70 mg injections using an autoinjector/pen (AI)/pen) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).</description>
          </group>
        </group_list>
        <measure>
          <title>CHU Substudy: Number of Participants Who Self-administered a Full Dose, Partial Dose, or No Dose of Erenumab</title>
          <description>To assess participants ability to administer a full dose of erenumab in home-use at day 29 (week 4) and day 57 (week 8), site staff called participants and asked whether the participant administered a full, partial, or no dose of erenumab. A full dose means that the entire volume of both prefilled syringes or autoinjector/pens were injected. Discontinued prior to dosing day indicates participants who had discontinued the investigational product and did not attempt to self-administer on day 29 or 57.</description>
          <population>Participants enrolled in the CHU substudy who received at least 1 dose of investigational product in the substudy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29 (week 4)</title>
              <category_list>
                <category>
                  <title>Full dose</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial dose</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Discontinued prior to dosing day</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (week 8)</title>
              <category_list>
                <category>
                  <title>Full dose</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial dose</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Discontinued prior to dosing day</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events in the Double-blind Treatment Phase</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a clinical trial subject, including worsening of a pre-existing medical condition and laboratory value changes that require treatment or adjustment in current therapy.&#xD;
AEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03:&#xD;
Mild; asymptomatic or mild symptoms&#xD;
Moderate; minimal, local or noninvasive intervention indicated; limiting daily activities&#xD;
Severe or medically significant but not immediately life-threatening; hospitalization indicated; disabling; limiting self-care&#xD;
Life-threatening consequences; urgent intervention indicated&#xD;
Death related to AE&#xD;
A serious adverse event is an AE that meets at least 1 of the following criteria:&#xD;
fatal&#xD;
life threatening&#xD;
requires in-patient hospitalization or prolongation of existing hospitalization&#xD;
results in persistent or significant disability/incapacity&#xD;
congenital anomaly/birth defect&#xD;
other medically important serious event</description>
        <time_frame>From first dose of study drug in the double-blind treatment phase until the first dose of study drug in the open-label treatment phase (12 weeks) or up to 12 weeks after last dose for participants who did not enter the open-label treatment phase.</time_frame>
        <population>Randomized participants who received at least one dose of investigational product (safety analysis set).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Erenumab 7 mg QM</title>
            <description>Participants received erenumab 7 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Erenumab 21 mg QM</title>
            <description>Participants received erenumab 21 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
          <group group_id="O4">
            <title>Erenumab 70 mg QM</title>
            <description>Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events in the Double-blind Treatment Phase</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a clinical trial subject, including worsening of a pre-existing medical condition and laboratory value changes that require treatment or adjustment in current therapy.&#xD;
AEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03:&#xD;
Mild; asymptomatic or mild symptoms&#xD;
Moderate; minimal, local or noninvasive intervention indicated; limiting daily activities&#xD;
Severe or medically significant but not immediately life-threatening; hospitalization indicated; disabling; limiting self-care&#xD;
Life-threatening consequences; urgent intervention indicated&#xD;
Death related to AE&#xD;
A serious adverse event is an AE that meets at least 1 of the following criteria:&#xD;
fatal&#xD;
life threatening&#xD;
requires in-patient hospitalization or prolongation of existing hospitalization&#xD;
results in persistent or significant disability/incapacity&#xD;
congenital anomaly/birth defect&#xD;
other medically important serious event</description>
          <population>Randomized participants who received at least one dose of investigational product (safety analysis set).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events (SAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to discontinuation of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Grade ≥ 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Grade ≥ 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Grade ≥ 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events in the Open-label Treatment Phase</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a clinical trial subject, including worsening of a pre-existing medical condition and laboratory value changes that require treatment or adjustment in current therapy.&#xD;
AEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03:&#xD;
Mild; asymptomatic or mild symptoms&#xD;
Moderate; minimal, local or noninvasive intervention indicated; limiting daily activities&#xD;
Severe or medically significant but not immediately life-threatening; hospitalization indicated; disabling; limiting self-care&#xD;
Life-threatening consequences; urgent intervention indicated&#xD;
Death related to AE&#xD;
A serious adverse event is an AE that meets at least 1 of the following criteria:&#xD;
fatal&#xD;
life threatening&#xD;
requires in-patient hospitalization or prolongation of existing hospitalization&#xD;
results in persistent or significant disability/incapacity&#xD;
congenital anomaly/birth defect&#xD;
other medically important serious event</description>
        <time_frame>From first dose in the open-label treatment phase up to 12 weeks (participants receiving 70 mg only) or 16 weeks (participants with dose increased to 140 mg) after the last dose; a maximum of 268 weeks.</time_frame>
        <population>All participants who received at least one dose of investigational product in the open-label treatment phase (open-label treatment phase set).</population>
        <group_list>
          <group group_id="O1">
            <title>OLTP: Erenumab 70 mg QM</title>
            <description>Participants received 70 mg erenumab QM from week 12 until implementation of Protocol Amendment 3 (07 April 2016) in the open-label treatment phase; median duration of exposure was 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>OLTP: Erenumab 140 mg QM</title>
            <description>After implementation of Protocol Amendment 3 (07 April 2016), participants still on study received erenumab 140 mg QM up to week 264 in the open-label treatment phase; median duration of exposure was 141 weeks.</description>
          </group>
          <group group_id="O3">
            <title>OLTP: Erenumab 70/140 mg QM</title>
            <description>Participants received 70 mg erenumab QM from the beginning of the OLTP (week 12). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events in the Open-label Treatment Phase</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a clinical trial subject, including worsening of a pre-existing medical condition and laboratory value changes that require treatment or adjustment in current therapy.&#xD;
AEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03:&#xD;
Mild; asymptomatic or mild symptoms&#xD;
Moderate; minimal, local or noninvasive intervention indicated; limiting daily activities&#xD;
Severe or medically significant but not immediately life-threatening; hospitalization indicated; disabling; limiting self-care&#xD;
Life-threatening consequences; urgent intervention indicated&#xD;
Death related to AE&#xD;
A serious adverse event is an AE that meets at least 1 of the following criteria:&#xD;
fatal&#xD;
life threatening&#xD;
requires in-patient hospitalization or prolongation of existing hospitalization&#xD;
results in persistent or significant disability/incapacity&#xD;
congenital anomaly/birth defect&#xD;
other medically important serious event</description>
          <population>All participants who received at least one dose of investigational product in the open-label treatment phase (open-label treatment phase set).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="383"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="383"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="323"/>
                    <measurement group_id="O2" value="216"/>
                    <measurement group_id="O3" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events (SAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to discontinuation of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Grade ≥ 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249"/>
                    <measurement group_id="O2" value="180"/>
                    <measurement group_id="O3" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Grade ≥ 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Grade ≥ 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CHU Substudy: Number of Participants With Treatment-emergent Adverse Events During the CHU Substudy</title>
        <description>AEs were graded using the CTCAE version 4.03:&#xD;
Mild; asymptomatic or mild symptoms&#xD;
Moderate; minimal, local or noninvasive intervention indicated; limiting daily activities&#xD;
Severe or medically significant but not immediately life-threatening; hospitalization indicated; disabling; limiting self-care&#xD;
Life-threatening consequences; urgent intervention indicated&#xD;
Death related to AE&#xD;
A serious adverse event is an AE that meets at least 1 of the following criteria:&#xD;
fatal&#xD;
life threatening&#xD;
requires in-patient hospitalization or prolongation of existing hospitalization&#xD;
results in persistent or significant disability/incapacity&#xD;
congenital anomaly/birth defect&#xD;
other medically important serious event An adverse device effect is any AE related to the use of a medical device, including AEs resulting from insufficient or inadequate instructions for use, any malfunction of the device, or use error or from intentional misuse of the device.</description>
        <time_frame>From first dose in the CHU substudy to end of substudy (up to 12 weeks)</time_frame>
        <population>Participants enrolled in the CHU substudy who received at least 1 dose of investigational product in the substudy.</population>
        <group_list>
          <group group_id="O1">
            <title>CHU Substudy: Erenumab 140 mg Prefilled Syringe</title>
            <description>Participants in the open-label treatment phase in the United States self-administered 140 mg erenumab via two 70 mg injections using a prefilled syringe (PFS) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).</description>
          </group>
          <group group_id="O2">
            <title>CHY SubStudy: Erenumab 140 mg Autoinjector/Pen</title>
            <description>Participants in the open-label treatment phase in the United States self-administered 140 mg erenumab via two 70 mg injections using an autoinjector/pen (AI)/pen) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).</description>
          </group>
        </group_list>
        <measure>
          <title>CHU Substudy: Number of Participants With Treatment-emergent Adverse Events During the CHU Substudy</title>
          <description>AEs were graded using the CTCAE version 4.03:&#xD;
Mild; asymptomatic or mild symptoms&#xD;
Moderate; minimal, local or noninvasive intervention indicated; limiting daily activities&#xD;
Severe or medically significant but not immediately life-threatening; hospitalization indicated; disabling; limiting self-care&#xD;
Life-threatening consequences; urgent intervention indicated&#xD;
Death related to AE&#xD;
A serious adverse event is an AE that meets at least 1 of the following criteria:&#xD;
fatal&#xD;
life threatening&#xD;
requires in-patient hospitalization or prolongation of existing hospitalization&#xD;
results in persistent or significant disability/incapacity&#xD;
congenital anomaly/birth defect&#xD;
other medically important serious event An adverse device effect is any AE related to the use of a medical device, including AEs resulting from insufficient or inadequate instructions for use, any malfunction of the device, or use error or from intentional misuse of the device.</description>
          <population>Participants enrolled in the CHU substudy who received at least 1 dose of investigational product in the substudy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Grade ≥ 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Grade ≥ 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Grade ≥ 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leading to discontinuation of IP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse device effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Anti-erenumab Antibodies During the Double-blind Treatment Phase</title>
        <description>Two validated assays were used to detect the presence of anti-erenumab antibodies. First, an electrochemiluminescent bridging immunoassay was used to detect binding antibodies (screening assay) and confirm antibodies (confirmatory assay) capable of binding erenumab. Second, a cell-based bioassay was used to test positive binding antibody samples for neutralizing activity against erenumab.&#xD;
Participants who developed anti-erenumab antibodies are participants who were negative or had no result at baseline but positive at any time postbaseline during the DBTP.&#xD;
If a sample was positive for binding antibodies and demonstrated neutralizing activity at the same time point, the participant was defined as positive for neutralizing antibodies.</description>
        <time_frame>12 weeks</time_frame>
        <population>Participants who received at least 1 dose of IP and with valid postbaseline antibody testing results.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
          <group group_id="O2">
            <title>Erenumab 7 mg QM</title>
            <description>Participants received erenumab 7 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
          <group group_id="O3">
            <title>Erenumab 21 mg QM</title>
            <description>Participants received erenumab 21 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
          <group group_id="O4">
            <title>Erenumab 70 mg QM</title>
            <description>Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Anti-erenumab Antibodies During the Double-blind Treatment Phase</title>
          <description>Two validated assays were used to detect the presence of anti-erenumab antibodies. First, an electrochemiluminescent bridging immunoassay was used to detect binding antibodies (screening assay) and confirm antibodies (confirmatory assay) capable of binding erenumab. Second, a cell-based bioassay was used to test positive binding antibody samples for neutralizing activity against erenumab.&#xD;
Participants who developed anti-erenumab antibodies are participants who were negative or had no result at baseline but positive at any time postbaseline during the DBTP.&#xD;
If a sample was positive for binding antibodies and demonstrated neutralizing activity at the same time point, the participant was defined as positive for neutralizing antibodies.</description>
          <population>Participants who received at least 1 dose of IP and with valid postbaseline antibody testing results.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Developed binding antibodies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Developed neutralizing antibodies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Anti-erenumab Antibodies During the Open-label Treatment Phase</title>
        <description>Two validated assays were used to detect the presence of anti-erenumab antibodies. First, an electrochemiluminescent bridging immunoassay was used to detect binding antibodies (screening assay) and confirm antibodies (confirmatory assay) capable of binding erenumab. Second, a cell-based bioassay was used to test positive binding antibody samples for neutralizing activity against erenumab.&#xD;
Participants who developed anti-erenumab antibodies are participants who were negative prior to the first OLTP dose but positive at any time during the OLTP, or participants with no data prior to first dose in OLTP with any post-baseline positive results.&#xD;
If a sample was positive for binding antibodies and demonstrated neutralizing activity at the same time point, the participant was defined as positive for neutralizing antibodies.</description>
        <time_frame>From week 12 up to 12 weeks (participants receiving 70 mg only) or 16 weeks (participants with dose increased to 140 mg) after the last dose; maximum 268 weeks.</time_frame>
        <population>Participants who received at least 1 dose of IP in the OLTP and with valid antibody testing results during the OLTP.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Erenumab 70/140 mg QM</title>
            <description>Participants randomized to placebo in the double-blind treatment phase received 70 mg erenumab QM from week 12 in the open-label treatment phase. After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM.</description>
          </group>
          <group group_id="O2">
            <title>Erenumab 7 mg QM / Erenumab 70/140 mg QM</title>
            <description>Participants randomized to erenumab 7 mg in the double-blind treatment phase received 70 mg erenumab QM from week 12 in the open-label treatment phase. After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM.</description>
          </group>
          <group group_id="O3">
            <title>Erenumab 21 mg QM / Erenumab 70/140 mg QM</title>
            <description>Participants randomized to erenumab 21 mg in the double-blind treatment phase received 70 mg erenumab QM from week 12 in the open-label treatment phase. After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM.</description>
          </group>
          <group group_id="O4">
            <title>Erenumab 70 mg QM / Erenumab 70/140 mg QM</title>
            <description>Participants randomized to erenumab 70 mg in the double-blind treatment phase received 70 mg erenumab QM from week 12 in the open-label treatment phase. After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Anti-erenumab Antibodies During the Open-label Treatment Phase</title>
          <description>Two validated assays were used to detect the presence of anti-erenumab antibodies. First, an electrochemiluminescent bridging immunoassay was used to detect binding antibodies (screening assay) and confirm antibodies (confirmatory assay) capable of binding erenumab. Second, a cell-based bioassay was used to test positive binding antibody samples for neutralizing activity against erenumab.&#xD;
Participants who developed anti-erenumab antibodies are participants who were negative prior to the first OLTP dose but positive at any time during the OLTP, or participants with no data prior to first dose in OLTP with any post-baseline positive results.&#xD;
If a sample was positive for binding antibodies and demonstrated neutralizing activity at the same time point, the participant was defined as positive for neutralizing antibodies.</description>
          <population>Participants who received at least 1 dose of IP in the OLTP and with valid antibody testing results during the OLTP.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Developed binding antibodies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Developed neutralizing antibodies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Double-blind Treatment Phase: From first dose of study drug in the DBTP until the first dose of study drug in the open-label treatment phase (12 weeks) or up to 12 weeks after last dose for participants who did not enter the open-label treatment phase. Open-label Treatment Phase: From first dose in the OLTP up to 12 weeks (participants receiving 70 mg only) or 16 weeks (participants with dose increased to 140 mg) after the last dose; maximum 268 weeks. CHU substudy: 12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DBTP: Placebo QM</title>
          <description>Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
        </group>
        <group group_id="E2">
          <title>DBTP: Erenumab 7 mg QM</title>
          <description>Participants received erenumab 7 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
        </group>
        <group group_id="E3">
          <title>DBTP: Erenumab 21 mg QM</title>
          <description>Participants received erenumab 21 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
        </group>
        <group group_id="E4">
          <title>DBTP: Erenumab 70 mg QM</title>
          <description>Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase.</description>
        </group>
        <group group_id="E5">
          <title>OLTP: Erenumab 70 mg QM</title>
          <description>Participants received 70 mg erenumab QM from week 12 until implementation of Protocol Amendment 3 (07 April 2016) in the open-label treatment phase; median duration of exposure was 104 weeks.</description>
        </group>
        <group group_id="E6">
          <title>OLTP: Erenumab 140 mg QM</title>
          <description>After implementation of Protocol Amendment 3 (07 April 2016), participants still on study received erenumab 140 mg QM up to week 264 in the open-label treatment phase; median duration of exposure was 141 weeks.</description>
        </group>
        <group group_id="E7">
          <title>OLTP: Erenumab 70/140 mg QM</title>
          <description>Participants received 70 mg erenumab QM from the beginning of the OLTP (week 12). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM.</description>
        </group>
        <group group_id="E8">
          <title>CHU Substudy: Erenumab 140 mg PFS</title>
          <description>Participants in the open-label treatment phase in the United States self-administered 140 mg erenumab via two 70 mg injections using a prefilled syringe (PFS) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).</description>
        </group>
        <group group_id="E9">
          <title>CHU Substudy: Erenumab 140 mg AI/Pen</title>
          <description>Participants in the open-label treatment phase in the United States self-administered 140 mg erenumab via two 70 mg injections using an autoinjector/pen (AI)/pen) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).</description>
        </group>
        <group group_id="E10">
          <title>CHU Substudy: Total</title>
          <description>Participants in the open-label treatment phase in the United States self-administered 140 mg erenumab via two 70 mg injections using a prefilled syringe or autoinjector/pen on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="49" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Developmental hip dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Primary hyperaldosteronism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Appendicitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Tubo-ovarian abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Metatarsalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Invasive lobular breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage III</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pelvi-ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Adnexa uteri cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="220" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="172" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="264" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="16" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="29" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="29" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="82" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="59" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="111" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="31" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="56" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="22" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="53" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="52" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="53" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="78" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="41" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="37" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="48" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="27" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="383"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="250"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="383"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

